Health care access and utilization among adult cancer survivors: Results from the National Institutes of Health “All of Us” Research Program

by Steven S. Coughlin, Jie Chen, Jorge E. Cortes
Published 2021-06-01

Establishing geothermometric constraints on the local geothermal gradients: Case study of the Eastern Cordillera Basin, Colombia

by Carlos A. Barrera, Carlos A. Vargas, Jorge E. Cortes
Published 2018-07-01

Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML

by Jorge E. Cortes, Tara L. Lin, Geoffrey L. Uy, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet
Published 2021-07-01

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review

by Jorge E. Cortes, Jane F. Apperley, Daniel J. DeAngelo, Michael W. Deininger, Vamsi K. Kota, Philippe Rousselot, Carlo Gambacorti-Passerini
Published 2018-12-01

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia

by Jorge E. Cortes, Marcos de Lima, Hervé Dombret, Elihu H. Estey, Sergio A. Giralt, Pau Montesinos, Christoph Röllig, Adriano Venditti, Eunice S. Wang
Published 2020-10-01

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)

by Lucia Masarova, C. Cameron Yin, Jorge E. Cortes, Marina Konopleva, Gautam Borthakur, Kate J. Newberry, Hagop M. Kantarjian, Carlos E. Bueso-Ramos, Srdan Verstovsek
Published 2017-11-01

Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.

by Jaroslav Jelinek, Vazganush Gharibyan, Marcos R H Estecio, Kimie Kondo, Rong He, Woonbok Chung, Yue Lu, Nianxiang Zhang, Shoudan Liang, Hagop M Kantarjian, Jorge E Cortes, Jean-Pierre J Issa
Published 2011-01-01

Upwelling increases net primary production of corals and reef-wide gross primary production along the Pacific coast of Costa Rica

by Ines eStuhldreier, Ines eStuhldreier, Celeste eSánchez-Noguera, Celeste eSánchez-Noguera, Florian eRoth, Florian eRoth, Jorge eCortés, Tim eRixen, Christian eWild, Christian eWild
Published 2015-12-01

Impact of frontline treatment approach on outcomes of myeloid blast phase CML

by Kapil Saxena, Elias Jabbour, Ghayas Issa, Koji Sasaki, Farhad Ravandi, Abhishek Maiti, Naval Daver, Tapan Kadia, Courtney D. DiNardo, Marina Konopleva, Jorge E. Cortes, Musa Yilmaz, Kelly Chien, Sherry Pierce, Hagop Kantarjian, Nicholas J. Short
Published 2021-06-01

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

by Prajwal Boddu, Gautam Borthakur, Mythili Koneru, Xuelin Huang, Kiran Naqvi, William Wierda, Prithviraj Bose, Elias Jabbour, Zeev Estrov, Jan Burger, Yesid Alvarado, April Deshmukh, Ami Patel, Antonio Cavazos, Lina Han, Jorge E. Cortes, Hagop Kantarjian, Michael Andreeff, Marina Konopleva
Published 2018-09-01

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

by Jorge E. Cortes, Florian H. Heidel, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos, Anna Candoni, Brian Leber, Mikkael A. Sekeres, Daniel A. Pollyea, Roxanne Ferdinand, Weidong Wendy Ma, Thomas O’Brien, Ashleigh O’Connell, Geoffrey Chan, Michael Heuser
Published 2020-07-01

Addition of All-Trans Retinoic Acid to the combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older Patients with AML Does Not Improve The Outcome in Those...

by Aziz eNazha, Carlos eBueso - Ramos, Eli eEstey, Stefan eFaderl, Susan eO'Brien, Micheal eFernandez, Martin eNguyen, Charles eKoller, Emil eFreireich, Miloslav eBeran, Sherry ePierce, Michael eKeating, Jorge eCortes, Hagop eKantarjian, Farhad eRavandi
Published 2013-09-01

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

by Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia‑Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo, Koichi Takahashi, Rita Assi, Ahmad S. Alotaibi, Maro Ohanian, Michael Andreeff, Jorge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi, Naval G. Daver
Published 2021-02-01

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

by Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia-Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo, Koichi Takahashi, Rita Assi, Ahmad S. Alotaibi, Maro Ohanian, Michael Andreeff, Jorge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi, Naval G. Daver
Published 2020-10-01

Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes

by Koichi Takahashi, Feng Wang, Kiyomi Morita, Yuanqing Yan, Peter Hu, Pei Zhao, Abdallah Abou Zhar, Chang Jiun Wu, Curtis Gumbs, Latasha Little, Samantha Tippen, Rebecca Thornton, Marcus Coyle, Marisela Mendoza, Erika Thompson, Jianhua Zhang, Courtney D. DiNardo, Nitin Jain, Farhad Ravandi, Jorge E. Cortes, Guillermo Garcia-Manero, Steven Kornblau, Michael Andreeff, Elias Jabbour, Carlos Bueso-Ramos, Akifumi Takaori-Kondo, Marina Konopleva, Keyur Patel, Hagop Kantarjian, P. Andrew Futreal
Published 2018-07-01